PRKDC and non-small cell lung carcinoma: The Hellmann cohort included 75 patients with NSCLC, including six patients with PRKDC mutations for whom progression‐free survival (PFS) was superior to that of PRKDC wild‐type patients [median, not reached (NR) vs. 6.8 months; HR, 0.2893; 95% CI, 0.1255–0.6672; P = 0.0650, Fig. 4E].